Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On December11, 2017, Aquinox Pharmaceuticals, Inc. (the “Company”) appointed Lloyd Mackenzie, the Company’s current Vice President, Early Stage Development and CMC, as Chief Operating Officer. In such capacity, Mr.Mackenzie will serve as the Company’s principal operating officer.

Mr.Mackenzie has served as our Vice President, Early Stage Development and CMC since March 2017 and prior to that served as Vice President, Technical Operations and Planning from May 2013 to March 2017 and Senior Director, Technical Operations from May 2008 to May 2013. From 2007 to 2008, Mr.Mackenzie served as a Research Scientist of Pharmaceutical Development at QLT. From 1999 to 2007, Mr.Mackenzie served as a Research Scientist of Inflazyme Pharmaceuticals Inc., a biotechnology company. Mr.Mackenzie is the author of 15 scientific publications and is an inventor on four patents. Mr.Mackenzie holds a B.Sc. in Biochemistry from Simon Fraser University. As a result of his promotion, Mr.Mackenzie will receive an increase in his annual salary to $360,000.

About Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.